1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 23,000 | 24,400 | 22:46 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHILOGEN Aktie jetzt für 0€ handeln | |||||
| 18.05. | Dividendenbekanntmachungen (18.05.2026) | 16.622 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,040 | -0,09 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,980 | +0,72 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| BEAM THERAPEUTICS | 26,710 | -0,52 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| BIOVIE | 1,540 | +21,26 % | New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results | Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies NEW YORK CITY, NY / ACCESS Newswire... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 386,66 | +4,31 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| TARSUS PHARMACEUTICALS | 70,02 | +0,80 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | Generated second quarter 2026 XDEMVY- net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million... ► Artikel lesen | |
| ALUMIS | 25,550 | +0,71 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 114,10 | +4,09 % | KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments | ||
| CLIMB BIO | 14,390 | +3,90 % | Climb Bio, Inc. - 10-Q, Quarterly Report | ||
| APOGEE THERAPEUTICS | 134,58 | -0,08 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,590 | +1,53 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 6,405 | -4,12 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,570 | -2,92 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MBX BIOSCIENCES | 66,97 | +1,45 % | MBX Biosciences GAAP EPS of -$0.78 | ||
| SIONNA THERAPEUTICS | 6,250 | +22,55 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen |
Das Unternehmen PHILOGEN SPA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,66 % bei einem Aktienkurs von 22,600 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 1,40 Euro errechnet sich eine Dividendendrendite von +6,19 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHILOGEN SPA finden Sie auf Wallstreet Online.